GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » PharmaCorp Rx Inc (TSXV:PCRX) » Definitions » EV-to-FCF

PharmaCorp Rx (TSXV:PCRX) EV-to-FCF : -23.51 (As of Apr. 08, 2025)


View and export this data going back to 2022. Start your Free Trial

What is PharmaCorp Rx EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PharmaCorp Rx's Enterprise Value is C$30.06 Mil. PharmaCorp Rx's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was C$-1.28 Mil. Therefore, PharmaCorp Rx's EV-to-FCF for today is -23.51.

The historical rank and industry rank for PharmaCorp Rx's EV-to-FCF or its related term are showing as below:

TSXV:PCRX' s EV-to-FCF Range Over the Past 10 Years
Min: -43.81   Med: -24.92   Max: 12.65
Current: -23.51

During the past 3 years, the highest EV-to-FCF of PharmaCorp Rx was 12.65. The lowest was -43.81. And the median was -24.92.

TSXV:PCRX's EV-to-FCF is ranked worse than
100% of 153 companies
in the Diversified Financial Services industry
Industry Median: 4.58 vs TSXV:PCRX: -23.51

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-08), PharmaCorp Rx's stock price is C$0.48. PharmaCorp Rx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was C$-0.030. Therefore, PharmaCorp Rx's PE Ratio (TTM) for today is At Loss.


PharmaCorp Rx EV-to-FCF Historical Data

The historical data trend for PharmaCorp Rx's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCorp Rx EV-to-FCF Chart

PharmaCorp Rx Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- -177.23 -11.98

PharmaCorp Rx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -26.58 -11.98 -9.89 0.64 -43.21

Competitive Comparison of PharmaCorp Rx's EV-to-FCF

For the Shell Companies subindustry, PharmaCorp Rx's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCorp Rx's EV-to-FCF Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, PharmaCorp Rx's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where PharmaCorp Rx's EV-to-FCF falls into.


;
;

PharmaCorp Rx EV-to-FCF Calculation

PharmaCorp Rx's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=30.064/-1.279
=-23.51

PharmaCorp Rx's current Enterprise Value is C$30.06 Mil.
PharmaCorp Rx's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-1.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmaCorp Rx  (TSXV:PCRX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

PharmaCorp Rx's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.48/-0.030
=At Loss

PharmaCorp Rx's share price for today is C$0.48.
PharmaCorp Rx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.030.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


PharmaCorp Rx EV-to-FCF Related Terms

Thank you for viewing the detailed overview of PharmaCorp Rx's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaCorp Rx Business Description

Traded in Other Exchanges
N/A
Address
303 Wellman Lane, Suite 203, Saskatoon, SK, CAN, S7T 0J1
Website
PharmaCorp Rx Inc foremerly Proton Capital Corp is a Capital Pool Company. The principal business of the company is to identify and evaluate assets or businesses with a view to potentially acquiring them or interest therein by completing a purchase transaction, by exercising an option, or by any concomitant transaction.

PharmaCorp Rx Headlines

From GuruFocus